Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

Palivizumab for the prevention of respiratory syncytial virus infection

Alexander L. Rogovik, Bruce Carleton, Alfonso Solimano and Ran Goldman
Canadian Family Physician August 2010; 56 (8) 769-772;
Alexander L. Rogovik
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Carleton
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfonso Solimano
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran Goldman
MD FRCPC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rgoldman@cw.bc.ca
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

ABSTRACT

QUESTION Palivizumab, a specific monoclonal antibody for respiratory syncytial virus (RSV), is available for prevention of pediatric respiratory tract infections. What are the indications for its use and can it be used for treatment of RSV infections?

ANSWER Most infants should not be considered for RSV prophylaxis with palivizumab. The drug is approved for use for different indications in different Canadian provinces. The drug should be administered only in the context of infants most vulnerable to severe RSV illness with a high likelihood of hospital admission, particularly in the first 6 months of life. It is not effective in the treatment of RSV disease and it is not approved or recommended for this indication.

Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis in young children worldwide, affecting almost all children by 2 years of age. Respiratory syncytial virus infection is the most common reason for admission to hospital in the first year of life and is responsible for most of the approximately 12 000 hospitalizations per year in children younger than 2 years of age in Canada.1 The RSV season lasts about 5 months in Canada, from December to April.2

Premature infants in their first 6 months, children with underlying cardiac or pulmonary disease in their first 2 years, immunocompromised children (particularly transplant patients), and healthy infants younger than 6 weeks of age are at the highest risk of severe RSV infection. These children are likely to have prolonged hospital stays, and are more likely to require admission to the intensive care unit (ICU) and to need mechanical ventilation.2 In older children and adults, RSV infection usually manifests as upper respiratory tract illness.

The absence of a vaccine to prevent RSV infection narrows preventive measures to a combination of public health advice and the use of passive immunization with palivizumab, the only licensed product available for prevention of RSV lower respiratory tract disease in high-risk infants and children during the RSV season. A previously used hyperimmune polyclonal RSV intravenous immunoglobulin, prepared from the plasma of donors selected for high serum titres of an RSV-neutralizing antibody, is no longer available.

Variability in indications

Respiratory syncytial virus is an RNA virus of the Paramyxoviridae family. The virus uses surface glycoproteins G and F, which lack neuraminidase and hemagglutinin activity, to infect cells. Palivizumab is a humanized mouse monoclonal immunoglobulin G1, comprising 95% human and 5% murine amino acid sequences. It is produced by recombinant DNA technology and directed against an epitope of the F glycoprotein of RSV. Palivizumab binds to this glycoprotein and prevents viral invasion of the host cells in the airway. This reduces viral activity and cell-to-cell transmission, and blocks the fusion of infected cells.3

Palivizumab has been approved for use in Canada since 2002. It is effective against both RSV subtypes (A and B). Palivizumab is administered intramuscularly at a dose of 15 mg/kg once every 30 days in a series of 5 monthly intramuscular injections to infants and children during the RSV season. The half-life for palivizumab is in the range of 18 to 21 days; therefore, monthly administration during the RSV season is enough for palivizumab to maintain its serum concentration at a protective level.3 The American Academy of Pediatrics recommends administering palivizumab for 5 consecutive months, covering the peak of the local RSV season.4

Clinical trials

The efficacy of palivizumab has been evaluated in 2 multicentre randomized controlled trials (RCTs), both of which used a primary end point of reduction in hospitalization owing to RSV infection.5,6 One RCT was conducted at 139 centres in the United States, the United Kingdom, and Canada. A total of 1502 children who were premature (ie, gestation for less than or equal to 35 weeks) or who had bronchopulmonary dysplasia (BPD) were randomized to receive injections of either palivizumab (15 mg/kg) or an equivalent volume of placebo by intramuscular injection every 30 days for 5 months.5 Palivizumab prophylaxis resulted in a 5.8% absolute reduction in hospitalization for RSV (10.6% placebo vs 4.8% palivizumab, number needed to treat [NNT] = 17). Children born premature but without BPD had a 6.3% reduction in RSV hospitalization (NNT = 16), while children with BPD had a 4.9% reduction (NNT = 20).5 The palivizumab group also had fewer total RSV hospital days and a lower incidence of ICU admissions, although ICU admission duration was significantly longer in the palivizumab group (P = .02, NNT = 37). There were no significant differences in adverse events between the 2 groups. Reactions at the site of injection were uncommon (1.8% placebo vs 2.7% palivizumab); the most frequent reaction was mild and transient erythema.5

In another RCT, 1287 children with hemodynamically significant congenital heart disease (CHD) received 5 monthly intramuscular injections of 15 mg/kg palivizumab or placebo.6 Palivizumab recipients had a 4.4% reduction in RSV hospitalizations (NNT = 23), a 56% reduction in total days of RSV hospitalization per 100 children, and a 73% reduction in total RSV hospital days with increased supplemental oxygen per 100 children. Adverse events were similar between the treatment groups and no child had the drug discontinued for a related adverse event.6 Therefore, monthly intramuscular injections of palivizumab (15 mg/kg per month) are well tolerated and effective for prophylaxis of serious RSV disease in young children with CHD or BPD.

The IMpact trial suggested an NNT of 16 to 20 infants treated with palivizumab to prevent 1 hospitalization, based on treating all infants born after less than 35 weeks’ gestation; a subsequent study of children with CHD suggested a similar NNT for children younger than 6 months of age. For children older than 6 months of age the NNT was 83.5,6

In general, cost-benefit analyses of palivizumab have found that because of its high cost there are no savings to be gained in health care dollars if all at-risk infants are offered prophylaxis, although some studies have yielded conflicting results.7–10 A recent systematic review and economic evaluation11 has shown that although palivizumab is clinically effective for reducing the risk of serious lower respiratory tract infection requiring hospitalization in high-risk children, if used unselectively in preterm infants without chronic lung disease (CLD) or children with CLD or CHD, the incremental cost-effectiveness ratio is double that which is considered to represent good value for money. However, prophylaxis with palivizumab might be cost-effective for premature children with CLD when they have 2 or more additional risks (male sex, intrauterine growth retardation, low birth weight, maternal smoking, rural residence, breastfeeding for 2 months or less, a birthday in November, December, and January, etc).11

Adverse effects

The most common reported adverse effects of palivizumab are local erythema, pain at the injection site, fever, and rash (1% to 3% of patients).5 In 2 small observational studies investigating the safety and immunological effects of repeated prophylaxis with palivizumab for a second year, no adverse clinical or immune effects were identified, although very rare cases of anaphylaxis have been reported following re-exposure to palivizumab.12,13 In a clinical trial, adverse events in infants with cardiac disease did not differ between treatment and placebo groups.6

Palivizumab is a recombinant product and has no potential for transmitting blood-borne infectious diseases. Moreover, it does not interfere with response to vaccines and does not affect the measles-mumps-rubella or other live virus immunization schedules.

Indications

Most infants should not be considered for RSV prophylaxis with palivizumab. Further, according to the American Academy of Pediatrics, palivizumab is not effective in the treatment of RSV infection and is not approved or recommended for this indication.4

Prophylaxis with palivizumab is only available for high-risk infants during the RSV season. Canadian indications for administration of palivizumab are shown in Table 1.14 According to the American Academy of Pediatrics, children eligible for a maximum of 5 doses include infants younger than 2 years of age who require medical therapy for CLD or CHD, premature infants born before 31 weeks’ gestation, and certain infants with neuromuscular disease or congenital abnormalities of the airways.4 Premature infants with a gestational age of 32 to 35 weeks with at least 1 risk factor and born 3 months before or during RSV season are eligible for a maximum of 3 doses.4

View this table:
  • View inline
  • View popup
Table 1.

Indications for administering palivizumab for RSV prophylaxis

Conclusion

Palivizumab should only be considered for infants most vulnerable to severe RSV illness with a high likelihood of hospitalization, particularly in the first 6 months of life. Palivizumab is not effective in the treatment of RSV disease and is not approved or recommended for this indication.

Notes

PRETx

Pediatric Research in Emergency Therapeutics

Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program (www.pretx.org) at the BC Children’s Hospital in Vancouver, BC. Dr Rogovik is Assistant Director, Dr Carleton and Dr Solimano are members, and Dr Goldman is Director of PRETx. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875-2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).

Footnotes

  • This article is eligible for Mainpro-M1 credits. To earn credits, go to www.cfp.ca and click on the Mainpro link.

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Mitchell I,
    2. Tough S,
    3. Gillis L,
    4. Majaesic C
    . Beyond randomized controlled trials: a “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol 2006;41(12):1167-74.
    OpenUrlPubMed
  2. 2.↵
    1. Wang EE,
    2. Law BJ,
    3. Boucher FD,
    4. Stephens D,
    5. Robinson JL,
    6. Dobson S,
    7. et al
    . Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1996;129(3):390-5.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Johnson S,
    2. Oliver C,
    3. Prince GA,
    4. Hemming VG,
    5. Pfarr DS,
    6. Wang SC,
    7. et al
    . Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176(5):1215-24.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Committee on Infectious Diseases,
    2. Bocchini JA Jr,
    3. Bernstein HH,
    4. Bradley JS,
    5. Brady MT,
    6. Byington CL,
    7. Fisher MC,
    8. et al
    . From the American Academy of Pediatrics: policy statements—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124(6):1694-701. Epub 2009 Sep 7.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. The IMpact-RSV Study Group
    . Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531-7.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Feltes TF,
    2. Cabalka AK,
    3. Meissner HC,
    4. Piazza FM,
    5. Carlin DA,
    6. Top FH Jr,
    7. et al
    . Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143(4):532-40.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Fitzgerald DA
    . Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Paediatr Respir Rev 2009;10(3):143-7. Epub 2009 Jul 15.
    OpenUrlCrossRefPubMed
  8. 8.
    1. Elhassan NO,
    2. Sorbero ME,
    3. Hall CB,
    4. Stevens TP,
    5. Dick AW
    . Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006;160(10):1070-6.
    OpenUrlCrossRefPubMed
  9. 9.
    1. Reeve CA,
    2. Whitehall JS,
    3. Buettner PG,
    4. Norton R,
    5. Reeve DM,
    6. Francis F
    . Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006;42(5):253-8.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Nuijten MJ,
    2. Wittenberg W,
    3. Lebmeier M
    . Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25(1):55-71.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Wang D,
    2. Cummins C,
    3. Bayliss S,
    4. Sandercock J,
    5. Burls A
    . Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008;12(36):iii, ix-x, 1-86.
    OpenUrlPubMed
  12. 12.↵
    1. Lacaze-Masmonteil T,
    2. Seidenberg J,
    3. Mitchell I,
    4. Cossey V,
    5. Cihar M,
    6. Csader M,
    7. et al
    . Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf 2003;26(4):283-91.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Null D Jr,
    2. Pollara B,
    3. Dennehy PH,
    4. Steichen J,
    5. Sánchez PJ,
    6. Givner LB,
    7. et al
    . Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 2005;24(11):1021-3.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Samson L,
    2. Canadian Paediatric Society, Infectious Diseases and Immunization Committee
    . Prevention of respiratory syncytial virus infection. Paediatr Child Health (Oxford) 2009;14(8):521-6.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Family Physician: 56 (8)
Canadian Family Physician
Vol. 56, Issue 8
1 Aug 2010
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Palivizumab for the prevention of respiratory syncytial virus infection
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Palivizumab for the prevention of respiratory syncytial virus infection
Alexander L. Rogovik, Bruce Carleton, Alfonso Solimano, Ran Goldman
Canadian Family Physician Aug 2010, 56 (8) 769-772;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Palivizumab for the prevention of respiratory syncytial virus infection
Alexander L. Rogovik, Bruce Carleton, Alfonso Solimano, Ran Goldman
Canadian Family Physician Aug 2010, 56 (8) 769-772;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Variability in indications
    • Clinical trials
    • Adverse effects
    • Indications
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Hypoxia inducible factors inhibit respiratory syncytial virus infection by modulation of nucleolin expression
  • Palivizumabs real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017
  • Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors
  • Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera
  • Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Child Health Update

  • Accidental cannabis ingestion in young children
  • All-terrain vehicle injuries in children and adolescents
  • Screen time and sleep in children
Show more Child Health Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire